Amy S. Rosenberg

7.4k citations

84 papers · 5.5k indexed · 2 hit papers · h-index 35

Molecular Biology top 5%
Immunology top 1%
Radiology, Nuclear Medicine and Imaging top 1%
Physiology top 2%
Rheumatology top 1%

Co-authors: Priya S. Kishnani Daniela Verthelyi Carrie Wagner David J. Shealy Nancy Solowski Bernie Scallon Xiaoyu Song Barry Cherney
Topics: Lysosomal Storage Disorders Research (18 papers)Immunotherapy and Immune Responses (17 papers)Monoclonal and Polyclonal Antibodies Research (15 papers)
Cited by: Immunology Radiology, Nuclear Medicine and Imaging Rheumatology
Journals: Nature The Journal of Experimental Medicine Journal of Clinical Oncology
Partner nations: United States Thailand Israel

In The Last Decade

Amy S. Rosenberg

84 papers receiving 5.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effects of protein aggregates: An immunologic perspective

2006 1.1k citations Amy S. Rosenberg The AAPS Journal profile →
Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists

2002 533 citations Amy S. Rosenberg et al. profile →

Peers

Countries citing papers authored by Amy S. Rosenberg

Since Specialization

Citations

This map shows the geographic impact of Amy S. Rosenberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy S. Rosenberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy S. Rosenberg more than expected).

Fields of papers citing papers by Amy S. Rosenberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy S. Rosenberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy S. Rosenberg. The network helps show where Amy S. Rosenberg may publish in the future.

Co-authorship network of co-authors of Amy S. Rosenberg

This figure shows the co-authorship network connecting the top 25 collaborators of Amy S. Rosenberg. A scholar is included among the top collaborators of Amy S. Rosenberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy S. Rosenberg. Amy S. Rosenberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Immunoinformatic Risk Assessment of Host Cell Proteins During Process Development for Biologic Therapeutics 2023 ·The AAPS Journal ·Kirk Haltaufderhyde,Brian Roberts,(unknown),Frances Terry,(unknown),(unknown),William Martin,Amy S. Rosenberg,Anne S. De Groot	10
2	Successful AAV8 readministration: Suppression of capsid‐specific neutralizing antibodies by a combination treatment of bortezomib and CD20 mAb in a mouse model of Pompe disease 2023 ·The Journal of Gene Medicine ·Su Jin Choi,John S. Yi,Jeong‐A Lim,Thomas F. Tedder,Dwight D. Koeberl,William R. Jeck,Ankit K. Desai,Amy S. Rosenberg,Baodong Sun,Priya S. Kishnani	11
3	In silico immunogenicity assessment for sequences containing unnatural amino acids: A method using existing in silico algorithm infrastructure and a vision for future enhancements 2022 ·PubMed ·(unknown),Andrés H. Gutiérrez,William Martin,Frances Terry,Brian Roberts,Amy S. Rosenberg,Anne S. De Groot	12
4	Transforming the clinical outcome in CRIM-negative infantile Pompe disease identified via newborn screening: the benefits of early treatment with enzyme replacement therapy and immune tolerance induction 2021 ·Genetics in Medicine ·Cindy Li,Ankit K. Desai,Punita Gupta,(unknown),Vikas Bhambhani,Robert J. Hopkin,Can Fıçıcıoğlu,Pranoot Tanpaiboon,William J. Craigen,Amy S. Rosenberg,Priya S. Kishnani	33
5	Identification of a potent regulatory T cell epitope in factor V that modulates CD4+ and CD8+ memory T cell responses 2021 ·Clinical Immunology ·Anne S. De Groot,Amy S. Rosenberg,S. M. Shahjahan Miah,Gail Skowron,Brian Roberts,(unknown),Frances Terry,William Martin	17
6	Lessons Learned to Date on COVID-19 Hyperinflammatory Syndrome: Considerations for Interventions to Mitigate SARS-CoV-2 Viral Infection and Detrimental Hyperinflammation 2020 ·Frontiers in Immunology ·Marco Cardone,(unknown),Amy S. Rosenberg,Montserrat Puig	36
7	Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort 2020 ·Frontiers in Immunology ·Ankit K. Desai,(unknown),John W. Sleasman,Amy S. Rosenberg,Priya S. Kishnani	28
8	The potential impact of timing of IVIG administration on the efficacy of rituximab for immune tolerance induction for patients with Pompe disease 2020 ·Clinical Immunology ·Ankit K. Desai,Amy S. Rosenberg,Priya S. Kishnani	2
9	Novel reference genes in colorectal cancer identify a distinct subset of high stage tumors and their associated histologically normal colonic tissues 2019 ·BMC Medical Genetics ·Lai Xu,Helen Luo,Rong Wang,Wells W. Wu,Je‐Nie Phue,Rong‐Fong Shen,Hartmut Juhl,Leihong Wu,(unknown),Vahan Simonyan,Lorraine Pelosof,Amy S. Rosenberg	17
10	Capnocytophaga spp. infection causing chorioamnionitis: an unusual suspect 2018 ·Anaerobe ·(unknown),Amy S. Rosenberg,(unknown),(unknown),Camille Hamula	4
11	High dose IVIG successfully reduces high rhGAA IgG antibody titers in a CRIM-negative infantile Pompe disease patient 2017 ·Molecular Genetics and Metabolism ·(unknown),Zoheb B. Kazi,Ankit K. Desai,(unknown),Amy S. Rosenberg,Priya S. Kishnani	11
12	Distinct Profiles for Mitochondrial t-RNAs and Small Nucleolar RNAs in Locally Invasive and Metastatic Colorectal Cancer 2015 ·Clinical Cancer Research ·Lai Xu,Joseph M. Ziegelbauer,Rong Wang,Wells W. Wu,Rong‐Fong Shen,Hartmut Juhl,Yaqin Zhang,Amy S. Rosenberg	27
13	Rescue of CD8+ T cell vaccine memory following sublethal γ irradiation 2015 ·Vaccine ·(unknown),Julia D. Berkson,(unknown),Abdel Elkahloun,Karen Mason,Amy S. Rosenberg	3
14	MHC Disparate Resting B Cells Are Tolerogenic in the Absence of Alloantigen-Expressing Dendritic Cells 2012 ·(unknown),Kazuhide Tsuji,Karen Mason,Amy S. Rosenberg	1
15	Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease 2012 ·Genetics in Medicine ·Suhrad G. Banugaria,Sean N. Prater,Judeth K. McGann,Jonathan Feldman,(unknown),Carrie Bailey,(unknown),Robert L. Conway,David Viskochil,Joyce A. Kobori,Amy S. Rosenberg,Priya S. Kishnani	70
16	Atypical immunologic response in a patient with CRIM-negative Pompe disease 2011 ·Molecular Genetics and Metabolism ·Mary‐Alice Abbott,Sean N. Prater,Suhrad G. Banugaria,Susan Richards,Sarah P. Young,Amy S. Rosenberg,Priya S. Kishnani	24
17	Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants 2009 ·Molecular Genetics and Metabolism ·Priya S. Kishnani,Paula Goldenberg,Stephanie DeArmey,James H. Heller,Danny Benjamin,Sarah P. Young,Deeksha Bali,Sue Ann Smith,Jennifer S. Li,Hanna Mandel,Dwight D. Koeberl,Amy S. Rosenberg,(unknown)	285
18	Peripheral Expression of Self-MHC-II Influences the Reactivity and Self-Tolerance of Mature CD4+ T Cells 2002 ·Immunity ·Avinash Bhandoola,Xuguang Tai,Michael Eckhaus,Hugh Auchincloss,Karen Mason,Steven A. Rubin,Kathryn M. Carbone,Zvi Grossman,Amy S. Rosenberg,Alfred Singer	77
19	Assessment of alloreactive T cell subpopulations of aged mice in vivo. CD4⁺ but not CD8⁺ T cell‐mediated rejection response declines with advanced age 1994 ·European Journal of Immunology ·Amy S. Rosenberg,Joan M. G. Sechler,(unknown),(unknown),Eda T. Bloom	13
20	Recognition Requirements for the Activation, Differentiation and Function of T‐Helper Cells Specific for Class I MHC Alloantigens 1987 ·Immunological Reviews ·(unknown),(unknown),Hana Golding,Amy S. Rosenberg,Toshiaki Mizuochi	56

About Amy S. Rosenberg

Amy S. Rosenberg is a scholar working on Immunology, Chemical Health and Safety and Biotechnology, having authored 84 papers that have together received 5.5k indexed citations. Recurring topics across this work include Lysosomal Storage Disorders Research (18 papers), Immunotherapy and Immune Responses (17 papers) and Monoclonal and Polyclonal Antibodies Research (15 papers). The work is most often cited by research in Immunology (1.6k citations), Radiology, Nuclear Medicine and Imaging (1.3k citations) and Rheumatology (733 citations). Amy S. Rosenberg has collaborated with scholars based in United States, Thailand and Israel. Frequent co-authors include Priya S. Kishnani, Daniela Verthelyi, Carrie Wagner, David J. Shealy, Nancy Solowski, Bernie Scallon, Xiaoyu Song, Barry Cherney, Zuben E. Sauna and Toshiaki Mizuochi. Their work appears in journals such as Nature, The Journal of Experimental Medicine and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact